HEMO CHINA at CSA and TISC 2021
July 10, 2021
HEMO CHINA was present at CSA & TISC 2021, this year’s edition of the Annual Scientific Session of Chinese Stroke Association (CSA) and Tiantan International
Innovative interventional solutions addressing neurovascular and peripheral diseases
We have built a suite of innovative interventional medical devices targeting neuro-vascular and peripheral diseases in China and the broader Asia-Pacific region. Our comprehensive portfolio of neuro-interventional medical devices covers the ischemic stroke, hemorrhagic stroke and neuro access fields. Under our peripheral intervention business, we offer a unique solution for the self-treatment of hemorrhoid symptoms and are also developing several other vascular intervention products for peripheral artery disease.
The Instalief™ hemorrhoid cooling balloon - the only one of its kind - offers a self-administered therapy for safe and effective relief of hemorrhoidal symptoms.
Our Afentta aspiration catheter offer neuro-interventionalists in China a differentiated tool for the treatment of acute ischemic stroke.
Our TracLine access catheter provides guiding access for other neuro interventional devices in the treatment of acute ischemic stroke, intracranial atherosclerosis and hemorrhagic stroke.
Our Latest News
HEMO Receives NMPA Approval for Afentta™ Aspiration Catheter
May 24, 2021
HEMO BIOENGINEERING LIMITED (“HEMO”), a Singapore-based medical device company with a focus on treating stroke patients, is pleased to announce that its Afentta™ intracranial thrombectomy
HEMO CHINA Recognised as 18th Top Medical Device Company in Future Medical VB100 List
April 19, 2021
Big congratulations go to our HEMO CHINA subsidiary for being recognized as the 18th Top Medical Device Company in this year’s prestigious Future Healthcare VB100
